. 2024 Mar 1;35(3):212–222. doi: 10.5152/tjg.2024.23071
Content of this journal is licensed under a Table 1.
Baseline Demographic and Clinical Characteristics of the Patients
| Characteristic | TACE-LEN Group (n = 51) |
TACE Group (n = 51) |
P |
|---|---|---|---|
| Gender | 3 | 3 | .715 |
| Female | 3 (5.88%) | 5 (9.8%) | 3 |
| Male | 48 (94.12%) | 46 (90.2%) | 3 |
| Age (years) | 3 | 3 | .898 |
| <65 | 42 (82.35%) | 44 (86.27) | 3 |
| ≥65 | 9 (17.65%) | 7 (13.73) | 3 |
| Child‒Pugh | 3 | 3 | .407 |
| A | 31 (60.78%) | 35 (68.63%) | 3 |
| B | 20 (39.22%) | 16 (31.37%) | 3 |
| Etiology | 3 | 3 | .4 |
| HBV | 45 (88.23%) | 47 (92.16%) | 3 |
| HCV | 2 (3.92%) | 0 (0%) | 3 |
| Without | 4 (7.85%) | 4 (7.84%) | 3 |
| AFP (ng/mL) | 3 | 3 | .887 |
| <400 | 26 (50.98%) | 31 (60.78%) | 3 |
| ≥400 | 25 (49.02%) | 20 (39.22%) | 3 |
| ALBI grade | 3 | 3 | .133 |
| 1 | 8 (15.69%) | 19 (37.26%) | 3 |
| 2 | 36 (70.59%) | 29 (56.86%) | 3 |
| 3 | 7 (13.72%) | 3 (3.88%) | 3 |
| BCLC | 3 | 3 | .83 |
| B | 15 (29.41%) | 16 (31.37%) | 3 |
| C | 36 (70.59%) | 35 (68.63%) | 3 |
| CNLC | 3 | 3 | 0.547 |
| IIb | 17 (33.33%) | 16 (31.37%) | 3 |
| IIIa | 16 (31.37%) | 21 (41.18%) | 3 |
| IIIb | 18 (35.3%) | 14 (27.45%) | 3 |
| MELD | 5.65 (−0.16 to 15.9) | 5.4 (−0.248 to 19.6) | .213 |
| HGB (g/L) | 136.02 ± 15.93 | 133.53 ± 19.85 | .165 |
| AST (U/L) | 39.5 (7.9-160.8) | 28 (10.4-243.5) | .677 |
| ALT (U/L) | 45.3 (14-646) | 36.9 (15-248) | .186 |
| PLT (× 109/L) | 112 (27-487) | 112 (31-227) | .51 |
| TB (µmol/L) | 3 | 3 | 0.455 |
| ≤17.1 | 18 (35.29%) | 18 (35.29%) | 3 |
| >17.1 | 33 (64.71%) | 33(64.71%) | 3 |
| Albumin (g/L) | 3 | 3 | .978 |
| <35 | 13 (25.49%) | 12 (23.53%) | 3 |
| ≥35 | 38 (74.51) | 39 (76.47%) | 3 |
| Cre (µmol/L) | 67(38-121) | 70(40-285) | 0.31 |
| CA19-9 (IU/mL) | 17.05 (2-1000) | 15.35 (2-195) | .45 |
| ALP (U/L) | 129 (45-1052) | 106 (38-325) | .631 |
| GGT (IU/L) | 117 (18-578) | 88 (16.3-737) | .576 |
| PT (seconds) | 10.9 (9.2-20.1) | 12.4 (9.2-22.9) | .775 |
| PTA (%) | 81.76 ± 16.68 | 76.33 ± 17.98 | .795 |
| INR | 1.09 (0.9-1.62) | 1.16 (0.89-2.27) | .213 |
| Vascular invasion | 3 | 3 | .427 |
| Yes | 25 (49.02%) | 29 (56.86%) | 3 |
| No | 29 (50.98%) | 22 (43.14%) | 3 |
| Extrahepatic metastasis | 3 | 3 | .29 |
| Yes | 19 (37.25%) | 14 (27.45%) | 3 |
| No | 32 (62.75%) | 37 (72.55%) | 3 |
| Number of TACE treatments | 2.92 ± 2.03 | 3.75 ± 1.97 | .503 |
AFP, alpha-fetoprotein; ALB, albumin; ALBI grade, albumin-bilirubin grade; ALP, alkaline phosphatase; AST, aspartate transaminase; BCLC, Barcelona Clinic Liver Cancer; CA19-9, carbohydrate antigen199; CNLC, China liver cancer staging; Cr, creatinine; GGT, γ-glutamyl transpeptidase; HBV, hepatitis B virus; HCV, hepatitis C virus; INR, international normalized ratio; PLT, platelet count; PT, prothrombin time; PTA, prothrombin time activity; TB, total bilirubin.